Premenstrual Syndrome (PMS) Treatment Market

By Drug Type;

Analgesics, Antidepressants, Oral Contraceptives, Gonadotropin-Releasing Hormone (GnRH) Analogues, Selective Serotonin Reuptake Inhibitors (SSRIs) and Others

By Product Type;

Prescription and OTC

By Distribution Channel;

Hospital Pharmacies and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn134735631 Published Date: September, 2025 Updated Date: October, 2025

Premenstrual Syndrome Treatment Market Overview

Premenstrual Syndrome Treatment Market (USD Million)

Premenstrual Syndrome Treatment Market was valued at USD 1,394.84 million in the year 2024. The size of this market is expected to increase to USD 1,715.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.0%.


Premenstrual Syndrome (PMS) Treatment Market

*Market size in USD million

CAGR 3.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)3.0 %
Market Size (2024)USD 1,394.84 Million
Market Size (2031)USD 1,715.48 Million
Market ConcentrationHigh
Report Pages337
1,394.84
2024
1,715.48
2031

Major Players

  • ABBVIE INC
  • AstraZeneca plc
  • BASF Corporation
  • Bayer AG.
  • Dr. Reddys Laboratories Ltd
  • Eli Lilly And Company.
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Shionogi Inc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Premenstrual Syndrome (PMS) Treatment Market

Fragmented - Highly competitive market without dominant players


The Premenstrual Syndrome Treatment Market is rapidly expanding due to rising awareness about the effects of hormonal fluctuations and the need for effective symptom relief. More than 60% of individuals experiencing PMS are actively seeking clinical and supportive care options. This shift is creating considerable opportunities for growth in both the pharmaceutical and therapeutic segments. The increasing focus on personalized care is driving new strategies and innovative solutions.

Innovation and Technological Advancements
Emerging solutions such as hormonal balancing agents, nutraceutical blends, and wearable health monitors are helping over 55% of affected users manage symptoms more effectively. These technological advancements are improving treatment personalization, especially with the integration of hormone therapy and digital monitoring. As these tools gain traction, they unlock new expansion potential and reflect an evolving trend toward patient-centric innovation.

Future Outlook and Growth Opportunities
With over 58% of developments focusing on integrated care, the future of this market lies in combined therapeutic approaches. From mood stabilizers to lifestyle-focused regimens, the demand is shifting toward well-rounded treatment offerings. This trend promises strong growth potential, as companies continue crafting forward-looking strategies that cater to a holistic model of care and evolving consumer expectations.

Expansion Through Research and Development
Over 61% of current R&D expenditure is aimed at advancing targeted drug discovery and innovative treatment designs. These investments are supporting the development of safer, more effective alternatives to traditional therapies. By focusing on clinical breakthroughs, companies are unlocking new avenues for market expansion and long-term competitive edge, further driven by a commitment to therapeutic innovation and quality care delivery.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Premenstrual Syndrome (PMS) Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing awareness of PMS
        2. Advances in treatment options
        3. Increasing female population
        4. Rising healthcare expenditure
        5. Demand for symptom relief
      2. Restraints
        1. Side effects of medication
        2. Cultural taboos around PMS
        3. Lack of effective diagnosis
        4. Limited access to healthcare
        5. Economic constraints
      3. Opportunities
        1. Development of novel therapies
        2. Expansion of market reach
        3. Technological innovations in treatment
        4. Focus on holistic approaches
        5. Emerging markets growth
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Premenstrual Syndrome (PMS) Treatment Market, By Drug Type, 2021 - 2031 (USD Million)
      1. Analgesics
      2. Antidepressants
      3. Oral Contraceptives
      4. Gonadotropin-Releasing Hormone (GnRH) Analogues
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Others
    2. Premenstrual Syndrome (PMS) Treatment Market, By Product Type, 2021 - 2031 (USD Million)
      1. Prescription
      2. OTC
    3. Premenstrual Syndrome (PMS) Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Others
    4. Premenstrual Syndrome (PMS) Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America

        1. Brazil

        2. Mexico

        3. Argentina

        4. Rest of Latin America

  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie
      2. BASF
      3. Bayer
      4. Dr. Reddy’s Laboratories
      5. Eli Lilly
      6. GlaxoSmithKline (GSK)
      7. H. Lundbeck
      8. Pfizer
      9. Shionogi
      10. Johnson & Johnson
      11. Teva Pharmaceutical Industries
      12. Viatris
      13. Novartis
      14. Sanofi
      15. Sun Pharmaceutical Industries
  7. Analyst Views
  8. Future Outlook of the Market